• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    LivaNova (LIVN) Gains Attention As CORE VNS Results Feed An Undervalued View

    Simply Wall St·11/01/2026 21:35:44
    Listen to the news

    LivaNova (NasdaqGS:LIVN) drew fresh attention after publishing 36 month CORE VNS study results in Neuromodulation, highlighting long term effectiveness and safety data for its vagus nerve stimulation therapy in drug resistant epilepsy.

    LivaNova’s recent CORE VNS data lands after a strong run in the shares, with a year to date share price return of 30.23% and a 1 year total shareholder return of 50.05%. However, the 90 day share price return has slipped 4.23%, hinting that enthusiasm has cooled a little in the short term while longer term holders are still well ahead.

    Scan beyond LivaNova and this epilepsy-focused update by reviewing 34 healthcare AI stocks, which are also trying to reshape treatment outcomes with data and device driven therapies.

    LivaNova now trades well above where it started the year, while the last quarter has cooled momentum. So is most of the upside already spent, or do the current fundamentals still leave meaningful room on the table?

    Most Popular Narrative: 13% Undervalued

    LivaNova last closed at $78.97, while the most followed narrative pegs fair value closer to $90.55. That gap reflects a view that recent clinical wins and capacity spending are not fully reflected in the current share price.

    The company is building a unified digital and AI enabled platform that starts with epilepsy, including clinician portals and a planned 2027 Bluetooth VNS generator for remote titration, then extends across obstructive sleep apnea, depression and cardiopulmonary, which can support higher recurring software and service revenue and stickier hardware usage that helps gross margin and free cash flow.

    See why 5 investors see LivaNova as 13% undervalued.

    Result: Fair Value of $90.55 (UNDERVALUED)

    Still, the current story for LivaNova could be knocked off course if elevated 2026 CapEx fails to lift earnings power or if epilepsy reimbursement support reverses.

    Find out about the key risks to this LivaNova narrative.

    Next Steps

    If this mix of optimism and caution around LivaNova leaves you on the fence, move quickly to inspect the details yourself and stress test the thesis against your own expectations, starting with the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond LivaNova?

    If LivaNova has sharpened your focus on quality, do not stop here. Use Simply Wall Street's screener to widen your options and pressure test your watchlist.